Group 1: Liquidity and Performance of Sci-Tech Pharmaceutical Index ETF - The Sci-Tech Pharmaceutical Index ETF had a turnover rate of 16.48% during the trading session, with a transaction volume of 37.98 million yuan, indicating active market trading [2] - Over the past week, the average daily transaction volume of the ETF reached 48.92 million yuan, ranking first among comparable funds [2] - In the past year, the ETF's scale increased by 154 million yuan, achieving significant growth and ranking first in new scale among comparable funds [2] - The ETF's shares grew by 130 million units in the past year, also ranking first in new shares among comparable funds [2] - As of June 10, the net value of the ETF increased by 25.51% over the past year [2] - The highest monthly return since inception was 23.29%, with the longest consecutive monthly gains being 4 months and a maximum increase of 21.76% [2] - The average monthly return during the rising months was 8.18%, with a historical one-year profit probability of 69.81% [2] Group 2: Market Trends and Investment Opportunities - The Central Committee of the Communist Party of China and the State Council issued opinions to improve the basic medical insurance drug catalog adjustment mechanism and to develop a commercial health insurance innovative drug catalog [3] - A report from Dongwu Securities indicated that there were 73 oral presentations from China at the 2025 ASCO, marking a historical high, with 89 out of 184 ADC pipeline studies coming from China, accounting for approximately 48.4% of the total [3] - The agency believes that the competitiveness of domestic innovative drugs in the global market is continuously improving, and international investors' confidence in Chinese innovative drug companies is increasing [3] - Domestic innovative drugs are transitioning from "catching up" to "leading," presenting significant investment opportunities [3] - Investors without stock accounts can access the Sci-Tech Biopharmaceutical ETF linked fund (021061) to capitalize on opportunities in the Sci-Tech Board biopharmaceutical sector [3]

Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index increased by 0.22% as of May 8, 2025, with notable gains from stocks such as Borui Pharmaceutical (+6.22%) and Maiwei Biotech (+3.68%) [1] - The Sci-Tech Pharmaceutical Index ETF (588700) rose by 0.42%, and over the past month, it has accumulated a 9.37% increase, ranking first among comparable funds [1] - The trading volume for the Sci-Tech Pharmaceutical Index ETF was 10.82 million CNY, with a turnover rate of 3.98% [3] Group 2 - The Sci-Tech Pharmaceutical Index ETF saw a significant growth in scale, increasing by 22.06 million CNY over the past two weeks, and its shares grew by 22.50 million [3] - The ETF experienced continuous net inflows over four days, with a peak single-day net inflow of 9.73 million CNY, totaling 26.61 million CNY [3] - As of April 30, 2025, the top ten weighted stocks in the index accounted for 53.3% of the total, including companies like United Imaging Healthcare and BeiGene [3] Group 3 - The biopharmaceutical industry maintained stable performance in Q1 2025, with 368 out of 371 listed companies reporting a total revenue of 280.68 billion CNY, a year-on-year decrease of 9.18%, and a net profit of 37.84 billion CNY [3] - The focus for investment in the pharmaceutical sector remains on innovative drug development, with an emphasis on leading companies in overseas markets and those combining innovative and generic drugs [3] - Investors without stock accounts can access the Sci-Tech Biopharmaceutical ETF linked fund (021061) for exposure to the sector [4]